Bozeman, Mont (April 5, 2011) — Today, Golden Helix announced that The University of Texas MD Anderson Cancer Center has licensed SNP & Variation Suite (SVS) for the sixth consecutive year as an integral part of their tool set for conducting research on the genetic factors linked to cancer.
SVS has enabled MD Anderson researchers to find novel associations in several different studies including lung cancer, rheumatoid arthritis, and primary biliary cirrhosis. Finding these associations is vital as researchers discover genetic indicators of all types of cancer.
SNP & Variation Suite is a powerful, integrated collection of high-performance analytic tools for managing, analyzing, and visualizing large-scale, complex genomic data. MD Anderson utilizes a server-based deployment so that the entire Epidemiology Department can use SVS to quickly and easily perform quality assurance, manipulate data, and analyze the findings of their studies.
Stated Josh Forsythe, Golden Helix’ vice president of sales and marketing, “We are honored to be working with such a leading organization as MD Anderson and look forward to the life-changing cancer discoveries they will undoubtedly make in the coming years. Their work is why we do what we do.”
About Golden Helix
Golden Helix is a leading bioinformatics organization, specializing in sequence and array-based SNP and copy number analysis, genetic association software, and analytic services. Our innovative technologies empower scientists to determine the genetic causes of disease, transform drug discovery, develop genetic diagnostics, and advance the quest for personalized medicine. Used by hundreds of researchers at the world's top pharmaceutical, biotech, and academic research organizations, Golden Helix products and services have been cited in over 400 peer-reviewed publications.
Golden Helix, Inc.